Solara Active Pharma Sciences Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/eemjil6cgrrc0qbbb5ihrai6.pdf

Key Takeaways


The Pondicherry Fire & Q3 Impact

Arun Kumar: "we have come with a very significant reset where we expect Solara to get back, within the next 5 quarters, to historic highs in terms of gross margins and EBITDA."

The Reset Strategy: Margin Over Growth


Rights Issue & Balance-Sheet Repair

Arun Kumar: "we as promoters are not only subscribing to our rights but are also willing to underwrite any unsubscribed portion simply because we believe that the post-COVID events leading to the poor performance of Solara is not necessarily a long-term situation."

Ibuprofen: A Bottom, Not a Recovery

Arun Kumar: "We strongly believe that the pricing has bottomed out. But I don't think there's going to be the pre-COVID price points on ibuprofen."

Working Capital & Operational Efficiency


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin run rateReturn to 20–22%By Q4 FY25
Q4 FY24 revenue₹400 croresQ4 FY24
Q4 FY24 EBITDA₹40 crores (quarterly)Q4 FY24
FY25 revenue₹1,500 croresFY25
Gross margin expansionFrom 42–44% to 51–52% (600 bps), Q-on-Q improvement starting Q1 FY25Gradual, through FY25
EBITDA margin expansion500–700 bps improvementThrough FY25
Debt-to-EBITDA ratioBelow 3, ideally 2.5Post rights issue
Free cash generation~₹150 crores (75% of EBITDA)FY25
Working capital days125–135 daysBy end of FY25
Recurring capex₹40–50 crores per yearOngoing

Key Metrics

MetricQ3 FY24
Revenue₹400 cr guided for Q4 FY24
FY25 revenue guidance₹1,500 cr
Gross margin42% to 44%, impacted by provisions and fire incident
Gross margin expansion targetat least 600 bps, from mid-40s to 51%-52%
EBITDA margin target20% to 22% by Q4 FY25, historical levels achieved in FY21 and FY22
Q4 FY24 EBITDA target₹40 cr per quarter
Q4 FY24 EBITDA margin~10% (per an analyst's math)
One-off impact₹100 cr, related to reset provisions and fire incident
Rights issue sizeup to ₹450 cr board approval, expected ₹350 cr to ₹400 cr
Recurring capex₹40 cr to ₹50 cr per year
Free cash generation expectation~₹150 cr next year, ~75% of EBITDA on ₹250 cr
Debt-to-EBITDA targetunder 3, ideally 2.5
Working capital cycle target125 to 135 days, ideal range 130 to 150 days
Ibuprofen pricing outlookbottomed out, but pre-COVID price points not expected to return